Research map: Biosimilar Rituximab in ANCA ‐Associated Vasculitis Compared to the Originator: A Multicenter Cohort Study

Back to the article

Papers in this map

  1. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides · J. Charles Jennette · 2012 · 6684 citations · Cited by this paper
  2. Cutaneous IgA Vasculitis in Primary Sjögren Disease: Findings From a Medical Record–Based Review · 2026 · Related
  3. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis · John H. Stone · 2010 · 2776 citations · Cited by this paper
  4. International Myositis Assessment and Clinical Studies Guidelines for Risk‐Based Cancer Screening: An External Validation in Patients With Dermatomyositis Seen at a Metropolitan Academic Center · 2026 · Related
  5. Modification and validation of the Birmingham Vasculitis Activity Score (version 3) · Chetan B. Mukhtyar · 2008 · 1253 citations · Cited by this paper
  6. How Do Open‐Ended Interview and Closed‐Ended Questionnaire Responses Compare? A Matched Mixed‐Methods Study Examining Treatment Attitudes of Patients With Meniscal Tear and Persistent Pain · 2026 · Related
  7. Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis · Loı̈c Guillevin · 2014 · 1101 citations · Cited by this paper
  8. Limitations of Hemophagocytic Lymphohistiocytosis Diagnostic Scoring in a Patient With Cirrhosis on Ursodiol: A Case Report · 2026 · Related
  9. RETRACTED: Avacopan for the Treatment of ANCA-Associated Vasculitis · David R.W. Jayne · 2021 · 1018 citations · Cited by this paper
  10. Comparison of Rule‐Based Algorithms to Identify Patients With Idiopathic Inflammatory Myopathies in Electronic Health Records · 2026 · Related
  11. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis · Michael W. Walsh · 2020 · 899 citations · Cited by this paper
  12. Quantification of Vascular Burden on Cranial Vessel Wall Magnetic Resonance Imaging and Ophthalmic Complications in Giant Cell Arteritis · 2026 · Related
  13. Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides · Andrew Exley · 1997 · 624 citations · Cited by this paper
  14. Lupus, a Leading Cause of Years of Potential Life Lost in Young Women: Implications for Public Health Priorities and Research Funding · 2026 · Related
  15. A disease-specific activity index for Wegener's granulomatosis: Modification of the Birmingham Vasculitis Activity Score · John H. Stone · 2001 · 471 citations · Cited by this paper
  16. Clinical Images: Achilles tendon rupture in rheumatoid arthritis · 2026 · Related
  17. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis · Pierre Charles · 2020 · 198 citations · Cited by this paper
  18. Tumor Necrosis Factor Inhibitor Treatment and Persistence Patterns in the Peripregnancy Period in Patients With Inflammatory Autoimmune Diseases · 2026 · Related
  19. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis · Rona Smith · 2020 · 177 citations · Cited by this paper
  20. Increased Risk of Environmental and Endemic Infectious Diseases in Sjögren's Disease: A Retrospective Analysis (2015–2023) · 2026 · Related
  21. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial · Rona Smith · 2023 · 132 citations · Cited by this paper
  22. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial · Won Seog Kim · 2017 · 76 citations · Cited by this paper
  23. A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis · Josef S Smolen · 2017 · 65 citations · Cited by this paper
  24. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial · Won Park · 2018 · 55 citations · Cited by this paper
  25. CanVasc Consensus Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitis: 2020 Update · Arielle Mendel · 2020 · 54 citations · Cited by this paper
  26. Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis · Clémence Thery-Casari · 2020 · 49 citations · Cited by this paper
  27. Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists · David C. Grabowski · 2015 · 42 citations · Cited by this paper
  28. Comparison of Two Rituximab Induction Regimens for Antineutrophil Cytoplasm Antibody–Associated Vasculitis: Systematic Review and Meta‐Analysis · Valérie Bénard · 2021 · 40 citations · Cited by this paper
  29. Extension Study of PF ‐05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis · Stanley B. Cohen · 2018 · 30 citations · Cited by this paper
  30. Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis—a real-life experience · Sakshi Mittal · 2020 · 24 citations · Cited by this paper
  31. Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis · Pierre Charles · 2020 · 18 citations · Cited by this paper
  32. Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA · Lianne Kearsley‐Fleet · 2023 · 14 citations · Cited by this paper
  33. Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade® to Remsima®? An Observational Study · Laixi Xue · 2020 · 13 citations · Cited by this paper
  34. Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator · Hyeok Chan Kwon · 2020 · 10 citations · Cited by this paper
  35. Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naïve to or switched from reference rituximab · Katarzyna Łosińska · 2023 · 7 citations · Cited by this paper
  36. Improving access to care for rheumatology services in Canada · Timothy S.H. Kwok · 2023 · 6 citations · Cited by this paper
  37. Analytical Similarity as Base for Rituximab Biosimilars in Lymphoid Malignancies in the Clinic: A PF-05280586 Case Study · Jeff Porter Sharman · 2022 · 5 citations · Cited by this paper
  38. Use of Rituximab for the Treatment of Antineutrophil Cytoplasm Antibody–associated Vasculitis in Canada, 2010–2020 · Arielle Mendel · 2021 · 4 citations · Cited by this paper
  39. Trimethoprim sulfamethoxazole prophylaxis and serious infections in granulomatosis with polyangiitis treated with rituximab · Arielle Mendel · 2024 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)